Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by MMABStraderon Jan 06, 2024 7:00pm
151 Views
Post# 35814140

RE:RE:RE:RE:RE:RE:RE:Back to our regularly scheduled program

RE:RE:RE:RE:RE:RE:RE:Back to our regularly scheduled program
My prediction is...once 90 test participants are reached, if there is not a serious possibility that in the following three to six months that the test will be stopped, or if Baxter doesn't approach Spectral management with talk about Baxter buyig Spectral, that at the next General Shareholder meeting in June, the Board will once again ask shareholders to approve a 1 : 10 reverse stock split and seek a U.S. listing by the end of the summer or early fall.. 

I don't think we would need a 1 : 20 reverse split like what has been requeted by the Board in the past because I think the share price will be about $1 U.S. by the end of June as the result of "exceeding" expectations which will definitely be disclosed, plus the Baxter milestone payment, plus PR that will emerge in the U.S. that Spectral will be seeking a U.S. listing.
<< Previous
Bullboard Posts
Next >>